{"filings":[{"id":760197,"accession_number":"0001104659-26-068647","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2026-06-01T12:59:50+00:00","items":["5.08"],"status":"ready","headline":"TransCode Therapeutics sets July 2, 2026 annual meeting; proposal deadline June 11","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for July 2, 2026; record date May 28, 2026.","Stockholder proposals for proxy inclusion due by June 11, 2026 (5:00 p.m. ET).","Director nominations and other business notices also due by June 11, 2026.","Meeting date moved more than 30 days from 2025 annual meeting (Aug 29, 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":648876,"accession_number":"0001104659-26-065959","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K/A","filed_at":"2026-05-26T10:43:50+00:00","items":["3.01"],"status":"ready","headline":"TransCode Therapeutics receives Nasdaq deficiency notice for low stockholders' equity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity reported at $1.25M as of March 31, 2026, below Nasdaq's $2.5M minimum.","Company has 45 days (until July 3, 2026) to submit a plan to regain compliance.","Plan hinges on stockholder approval to convert Series A Preferred Stock into common equity.","If plan is rejected or compliance not regained within extension, Nasdaq may delist RNAZ.","Failure to obtain approval by Dec 31, 2026 could trigger redemption of Series A Preferred at fair value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":609756,"accession_number":"0001104659-26-065728","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2026-05-22T20:15:37+00:00","items":["3.01"],"status":"ready","headline":"TransCode Therapeutics receives Nasdaq deficiency notice for low stockholders' equity of $1.25M vs $2.5M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity as of March 31, 2026 was $1,251,427, below Nasdaq's $2,500,000 minimum requirement.","Company has 45 days (until July 3, 2026) to submit a compliance plan to Nasdaq.","If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.","Failure to regain compliance could lead to delisting of common stock (RNAZ) from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95952,"accession_number":"0001104659-26-040171","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"TransCode secures up to $20M flexible financing from Yorkville via SEPA and convertible notes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $14M SEPA for common stock sales at 97% of lowest 3-day VWAP; up to $6M in pre-paid convertible notes at 5% discount.","First $1M convertible note tranche expected upon filing Form 10-K; second $5M tranche after registration and shareholder approval.","Convertible notes bear 5% interest, mature 18 months, convertible at 115% of prior day VWAP or 95% of lowest 7-day VWAP, floor at 20% of last trade.","Company issued 29.89 Series A Preferred shares as PIK dividend to DEFJ and Tungsten from prior acquisition on April 6, 2026.","CEO states financing extends runway into late 2027/early 2028, enabling completion of Phase 2a trial for TTX-MC138."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109409,"accession_number":"0001104659-26-022830","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["3.02","8.01","3.03","5.03","7.01","9.01"],"status":"ready","headline":"TransCode acquires exclusive license to oncolytic immunotherapy platform in all-stock deal","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Issued 1,136,364 shares of Series C non-voting convertible preferred to Unleash; convertible to common after stockholder approval.","Preferred stock represents 6.8% of TransCode's fully diluted common stock.","Lead candidate UIO-524 targets muscle-invasive bladder cancer (MIBC), a high-unmet-need indication.","License is exclusive, worldwide, fully paid-up, royalty-free; no future cash payments.","Tungsten Advisors received 77,841 Series C shares as financial advisor compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109408,"accession_number":"0001104659-26-018362","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"TransCode publishes preclinical RIG-I agonist data in Molecular Imaging and Biology","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Manuscript published Feb 19, 2026 in Molecular Imaging and Biology.","Novel template-driven RIG-I agonist activates innate immunity selectively in tumor cells.","Uses overexpressed miRNA-21 as intracellular assembly template; aims to reduce systemic toxicity.","Study conducted with Prof. Anna Moore (Michigan State Univ.) and TransCode CSO Zdravka Medarova.","TTX nanoparticle delivery platform underpins the approach; currently in clinical trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109407,"accession_number":"0001104659-26-010668","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"TransCode submits IND amendment for Phase 2a trial of TTX-MC138 in colorectal cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IND amendment filed with FDA for Phase 2a dose-expansion trial of TTX-MC138 in colorectal cancer patients with ctDNA-positive MRD.","Trial to enroll up to 45 patients who completed curative-intent therapy; expected start in first half 2026.","Study conducted by Quantum Leap Healthcare within PRE-I-SPY platform, its first expansion into colorectal cancer.","Principal Investigator Dr. Paula Pohlmann of MD Anderson Cancer Center leads the trial.","Collaboration with Quantum Leap and support from Colorectal Cancer Alliance; trial ID NCT05868226."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109406,"accession_number":"0001104659-26-001097","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"TransCode publishes preclinical data showing TTX-MC138 improves survival in glioblastoma models","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study in Journal of Functional Biomaterials shows TTX-MC138 delivered to GBM tumors after IV injection.","TTX-MC138 induced 5-fold increase in apoptotic activity and statistically significant survival extension.","IND-enabling studies completed; TTX-MC138 already in Phase 1a for metastatic solid tumors.","Phase 2a clinical trial for TTX-MC138 anticipated to begin in first half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125873,"accession_number":"0001104659-25-124226","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K/A","filed_at":"2025-12-23T23:59:59+00:00","items":["9.01","8.01"],"status":"ready","headline":"TransCode files ABCJ financials; acquired co's accumulated deficit $193M, DEFJ holds 90.8% voting power","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["ABCJ (parent of Polynoma) reported 2024 net loss of $16.4M and accumulated deficit of $193M.","Key asset is phase 3-ready seviprotimut-L for melanoma; intangible asset valued at $14M.","Post-acquisition, DEFJ holds ~90.8% voting power on fully diluted basis, raising controlled-company concerns.","Acquisition carries a repurchase option for DEFJ, potentially requiring cash settlement and disrupting operations.","Pro forma combined financial statements for Sep 30, 2025 and Dec 31, 2024 filed as Exhibit 99.3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125879,"accession_number":"0001104659-25-123500","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"TransCode Therapeutics appoints Jack Stover to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jack Stover appointed to Board effective Dec 19, 2025; joins Audit and Nominating Committees.","Dr. Magda Marquet resigns from Audit Committee following Stover's appointment.","Stover brings over 30 years life sciences leadership; currently Chairman of Traws Pharma (TRAW).","Previously CEO of Antares Pharma (ANTR), led sale to Halozyme for over $900 million.","Stover is designated as independent director and financial expert."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125878,"accession_number":"0001104659-25-120146","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"TransCode partners with Quantum Leap for Phase 2a trial of TTX-MC138 in colorectal cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration with Quantum Leap to evaluate TTX-MC138 in PRE-I-SPY Phase 2a dose-expansion trial.","Trial enrolls up to 45 colorectal cancer patients with ctDNA positivity after curative-intent therapy.","Phase 2a expected to start first half 2026; led by Dr. Paula Pohlmann of MD Anderson Cancer Center.","Decision based on positive Phase 1 safety data and durable anti-tumor effects.","TTX-MC138 targets metastatic disease; aims to intervene in minimal residual disease setting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125877,"accession_number":"0001104659-25-102361","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"TransCode amends preferred stock terms: caps conversion at 19.9% of Oct 8 common, removes delisting conversion right","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Amended and Restated Certificate of Designation for Series A and B Preferred on Oct 27, 2025.","Caps aggregate conversion at 19.9% of common outstanding as of Oct 8, 2025, per Nasdaq listing rules.","Removed holders' right to convert preferred into common upon delisting from Nasdaq.","Amendment approved by majority of preferred holders and board; no new shares issued.","Expects proxy statement for conversion approval and change-of-control proposals under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125872,"accession_number":"0001104659-25-100456","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K/A","filed_at":"2025-10-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"TransCode Therapeutics creates CVRs entitling holders to 50% of net proceeds from TTX-MC138 asset sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Each share of common stock held as of Oct 20, 2025 receives one CVR; CVRs pay 50% of Net Proceeds from future Upfront or Milestone payments on TTX-MC138 program disposals.","CVR term is 7 years from Oct 8, 2025; distributions paid quarterly within 60 days after each quarter end, starting with Q4 2025 if proceeds are received.","CVRs are non-transferable except by Permitted Transfers (inheritance, court order, merger); no certificates, book-entry only via DTC.","Vstock Transfer, LLC appointed as Rights Agent; Company must deliver payment statement and funds to Rights Agent within 60 days of each quarter.","Net Proceeds = Gross Proceeds minus Permitted Deductions (taxes, out-of-pocket costs, business development expenses, etc.)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125876,"accession_number":"0001104659-25-099029","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TransCode completes Phase 1a of TTX-MC138; 44% stable disease rate, moves to Phase 2a","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["16 patients treated across 4 dose levels; no dose-limiting toxicities or significant safety events observed.","Median treatment duration of 4 months (range 2–12); three patients remain on trial.","44% (7/16) achieved stable disease lasting ≥4 months per RECIST; one thyroid cancer patient had undetectable thyroglobulin.","Recommended Phase 2 dose established; company plans to initiate Phase 2a efficacy trial.","PK profile shows predictable exposure; pharmacodynamic effects consistent with preclinical models and prior Phase 0."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125875,"accession_number":"0001104659-25-097799","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["1.01","5.03","2.01","3.02","3.03","5.02","7.01","9.01"],"status":"ready","headline":"TransCode acquires ABCJ, gets $25M investment from DEFJ, appoints new CEO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of ABCJ for 83,285 common shares (9.99% of pre-close), convertible preferred, and up to $95M milestone payments.","DEFJ invests $25M via Series B convertible preferred ($20M cash + $5M promissory note due Jan 1, 2026 at 4% interest).","Shareholders as of Oct 20, 2025 receive one CVR per share entitling to 50% of future milestone proceeds (7-year term).","Philippe Calais appointed CEO; Thomas Fitzgerald remains CFO; Elizabeth Czerepak joins board and chairs Audit Committee.","Filed Certificate of Designation for Series A and B non-voting convertible preferred stock with PIK dividends and conversion rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125871,"accession_number":"0001104659-25-097919","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K/A","filed_at":"2025-10-08T23:59:59+00:00","items":["1.01","5.03","9.01"],"status":"ready","headline":"TransCode acquires ABCJ from CK Life Sciences unit; raises $25M in concurrent investment","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of ABCJ from DEFJ (CK Life Sciences sub) for 83,285 common and 1,152.9568 Series A Preferred shares.","Concurrent investment: DEFJ buys 223.7337 Series B Preferred at $111,740/share, raising ~$25M ($20M cash + $5M promissory note at 4% due Jan 2026).","Up to $95M in contingent milestone payments to DEFJ upon achievement of certain milestones.","Each common shareholder receives one CVR, entitling holder to 50% of net proceeds from upfront/milestone payments over 7 years.","Stockholder meeting needed to approve conversion of Series A Preferred and change of control under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125874,"accession_number":"0001104659-25-096658","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"TransCode Therapeutics amends MGH license; milestone payments doubled to $2.95M per patent family","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Amendment to Exclusive Patent License Agreement with Massachusetts General Hospital, effective August 15, 2025.","Updated timelines for pre-sales requirements for Patent Family 1 and Patent Family 2.","Aggregate one-time milestone payments increased from $1.55M to $2.95M for each patent family.","Individual milestone amounts for therapeutic product/process milestones also updated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142636,"accession_number":"0001104659-25-086442","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"TransCode shareholders elect directors and approve stock plan increase at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected directors Philippe Calais, Thomas Fitzgerald, Erik Manting, Magda Marquet; each received >84K votes for.","Approved amendment to 2021 stock plan increasing authorized shares by 166,724; 76,322 for, 18,310 against, 1,434 abstained.","Ratified WithumSmith+Brown as auditor for FY2025: 301,629 for, 7,844 against, 2,810 abstain; no broker non-votes.","Adjournment proposal passed but not needed because sufficient votes existed for the stock plan amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160697,"accession_number":"0001104659-25-059362","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"TransCode sets 2025 annual meeting Aug 29; proposal deadline June 23","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2025 Annual Meeting scheduled for August 29, 2025; record date July 11, 2025.","Stockholder proposals under Rule 14a-8 must be submitted by close of business on June 23, 2025.","Director nominations and other business also due by June 23, 2025 under universal proxy rules.","Meeting date is more than 30 days from June 13, 2024 annual meeting, triggering adjusted deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160696,"accession_number":"0001104659-25-045598","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"TransCode receives Nasdaq delisting notice; plans to appeal bid-price deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company received Nasdaq notice on May 6, 2025 for failing to maintain $1.00 minimum bid price for 30 consecutive days (Mar 24–May 5).","Due to multiple reverse stock splits over prior two years (cumulative ratio >=250:1), Company is ineligible for standard compliance period; must appeal by May 13, 2025.","TransCode plans to timely request a hearing before a Nasdaq Hearings Panel; delisting stayed pending hearing outcome.","No assurance the Company will ultimately regain compliance or remain listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160695,"accession_number":"0001104659-25-044596","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"TransCode Therapeutics announces 1-for-28 reverse stock split effective May 15, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1-for-28 ratio; effective 12:01 a.m. ET on May 15, 2025.","Outstanding shares reduced from 23,341,336 to approximately 833,620; par value unchanged.","No fractional shares issued; rounding up to nearest whole share for record holders.","Split intended to meet Nasdaq minimum bid price requirement; CUSIP changes to 89357L501.","Stockholder approval obtained May 2, 2025; trading symbol remains RNAZ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160694,"accession_number":"0001104659-25-044126","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"TransCode Therapeutics announces 1-for-28 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 1-for-28 reverse split on May 2, 2025; board ratified the ratio.","Outstanding shares will reduce from about 23.3M to approximately 833,620.","No fractional shares issued; fractional shares rounded up to nearest whole share.","Effective date to be announced at least two business days prior to implementation.","Split designed to meet Nasdaq minimum bid price requirement for continued listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160693,"accession_number":"0001104659-25-036866","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"TransCode adjourns special meeting due to lack of quorum; reconvenes May 2 for reverse split vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Only 12.73% of outstanding shares voted at April 21 special meeting; quorum required one-third.","Adjourned meeting reconvenes May 2, 2025 at 9:30 a.m. ET virtually at www.virtualshareholdermeeting.com/RNAZ2025SM2.","Proposal 1: reverse stock split at ratio from 1:10 to 1:40, board discretion.","Proposal 2: adjournment if needed; record date still April 2, 2025.","New vote deadline May 1, 2025 at 11:59 p.m. ET; company continues solicitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178901,"accession_number":"0001104659-25-027565","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"TransCode announces $10M registered direct offering of 10.25M shares and warrants at $0.98/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$10M from sale of 10.25M shares and 10.25M warrants at $0.98/unit.","Warrants exercisable at $0.86/share, immediately exercisable, 5-year term.","Placement agent receives warrants for 512,500 shares at $1.07/share.","Net proceeds to fund clinical trials for lead candidate TTX-MC138 and working capital.","Offering expected to close March 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178900,"accession_number":"0001104659-25-016947","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"TransCode shareholders approve warrant adjustments and share issuance at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal One approved: full issuance of shares upon exercise of Series C and D warrants with floor price of $2.4882.","Proposal Two approved: adjournment if needed to solicit more votes; not used as Proposal One passed.","Vote on Proposal One: 130,226 for, 51,288 against, 8,722 abstained; 190,236 shares present (quorum).","Total shares entitled to vote: 523,261; no broker non-votes on either proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178899,"accession_number":"0001104659-25-009122","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"TransCode Therapeutics adjourns special meeting; only 29.94% of shares voted, below quorum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held Feb 4, 2025 lacked quorum (needs one-third of outstanding shares); only 29.94% voted.","Meeting reconvenes Feb 25, 2025 at 9:30 a.m. ET virtually; record date remains Dec 17, 2024.","Proposals include approval of warrant share issuance (Series C and D) and an adjournment proposal.","Company continues soliciting votes; stockholders can vote by mail, internet, phone, or at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195575,"accession_number":"0001104659-24-130812","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TransCode opens Phase 1 Cohort 3; PK/PD from Cohort 1 show 66% miR-10b inhibition at 24h","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Safety Review Committee approved third cohort after no significant safety/DLTs in Cohort 2.","Cohort 3 dose will be approximately double the Cohort 2 dose; enrollment ongoing.","Cohort 1 PK/PD data consistent with preclinical and Phase 0; 66% miR-10b inhibition at 24h post-infusion.","Plasma concentration of TTX-MC138 in humans exceeded nonclinical levels, suggesting favorable PK.","Several patients from Cohorts 1 and 2 remain on study for continued treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195574,"accession_number":"0001104659-24-124597","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"TransCode raises ~$8M in private placement; expects to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 21.2M shares/pre-funded warrants, 21.2M Series C and 21.2M Series D warrants at $0.377/unit.","Warrants exercisable at $0.475; Series C 5-year term, Series D 2.5-year term after stockholder approval.","Gross proceeds ~$8M; proceeds for working capital and general corporate purposes.","Regained compliance with Nasdaq $2.5M minimum equity requirement after private placement; awaiting final determination.","Benchmark Company acted as exclusive placement agent; cash fee $50,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195573,"accession_number":"0001104659-24-124097","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2024-11-29T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"TransCode Therapeutics announces 1-for-33 reverse stock split effective Dec 4, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-33; effective 12:01 a.m. ET Dec 4, 2024; new CUSIP 89357L402.","Post-split shares outstanding approx 696,233 (includes recent private placement shares).","Split intended to regain compliance with Nasdaq minimum $1.00 bid price; no assurance of continued listing.","Fractional shares rounded up; no change in authorized shares; symbol RNAZ remains.","Vstock Transfer acting as exchange agent; stockholders need not take action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195572,"accession_number":"0001104659-24-122379","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"TransCode shareholders approve 10M share offering and reverse stock split at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ratified issuance of 10M shares of common stock and warrants to ThinkEquity LLC via best-efforts public offering.","Approved reverse stock split at ratio between 1:10 and 1:40, with timing at Board's discretion.","Ratification Proposal: 3,659,491 for, 1,094,753 against, 70,611 abstain (4,655,205 broker non-votes).","Reverse Stock Split Proposal: 7,271,421 for, 2,012,687 against, 195,952 abstain; no broker non-votes.","Adjournment Proposal approved but not needed; total shares present at meeting: 9,480,060 of 17,265,658 entitled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195571,"accession_number":"0001104659-24-114773","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"TransCode gets Nasdaq extension to regain compliance; Public Reprimand issued","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel granted extension to comply with Bid Price Rule 5550(a)(2), Equity Rule 5550(b), and Shareholder Approval Rule 5635(d).","Company issued 10M shares at $0.30 on July 22, 2024, a 62% discount to the $0.7925 minimum price, without shareholder approval.","Panel issued a Public Reprimand Letter for the unauthorized issuance; company remains listed subject to conditions.","TransCode must demonstrate compliance with listing rules within the extension period or face delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211834,"accession_number":"0001104659-24-103706","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq notifies TransCode of shareholder approval violation; adds to delisting risk","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received new Nasdaq deficiency letter on Sep 23, 2024 for failing to obtain shareholder approval for a deeply discounted offering.","Offering on July 22, 2024 of 10M shares at $0.30/share (62% discount to Minimum Price) represented 137% of pre-transaction shares.","Nasdaq determined discount >50% precludes public offering treatment, so shareholder approval was required under Rule 5635(d).","This deficiency is an additional basis for delisting, beyond prior Minimum Bid Price and Stockholders' Equity deficiencies.","Panel hearing scheduled for Oct 1, 2024 will consider all deficiencies; no assurance of continued listing on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211833,"accession_number":"0001104659-24-093614","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"TransCode Therapeutics faces Nasdaq delisting over bid price and equity deficiencies; hearing Oct 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Minimum Bid Price Deficiency Letter received Aug 13; stock below $1.00 for 30 consecutive days through Aug 12.","Not eligible for compliance period due to two reverse stock splits in past two years with cumulative ratio >250:1.","Stockholders' Equity Deficiency Letter received Aug 15; equity at June 30, 2024 was $1,322,274, below $2.5M requirement.","Raised ~$2.4M in July 2024 equity offering; pro forma equity ~$3.7M, but no assurance Staff will accept pro forma.","Nasdaq Hearing Panel will consider appeal on October 1, 2024; delisting action stayed pending decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211832,"accession_number":"0001104659-24-090559","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"TransCode receives two Nasdaq deficiency notices; faces potential delisting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Aug 13, 2024, Nasdaq notified TransCode of minimum bid price deficiency; stock closed below $1.00 for 30 consecutive days.","On Aug 15, 2024, Nasdaq notified of stockholders' equity deficiency; reported equity $1.32M vs $2.5M minimum.","Company is ineligible for 180-day compliance period due to two reverse stock splits in prior 2 years with cumulative ratio >250:1.","Company intends to request a hearing before Nasdaq Hearings Panel to stay any suspension/delisting action.","Pro forma equity with $2.4M July 2024 offering is ~$3.7M, but Staff acceptance is uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211831,"accession_number":"0001104659-24-082155","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"TransCode Therapeutics prices $3.0M public offering of 10M shares at $0.30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 10,000,000 common shares at $0.30 per share for gross proceeds of $3.0M.","Placement agent warrants to purchase 500,000 shares at $0.375, expiring July 22, 2029.","Expected close on July 24, 2024; proceeds for TTX-MC138 clinical trials and working capital.","ThinkEquity acting as sole placement agent; securities offered via effective S-3 shelf."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230606,"accession_number":"0001104659-24-071514","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K/A","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"TransCode Therapeutics shareholders reject reverse stock split proposal at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse stock split proposal failed: 1,018,164 for, 1,277,915 against, 96,498 abstain.","All four director nominees elected: Philippe Calais, Thomas Fitzgerald, Erik Manting, Magda Marquet.","Stock plan amendment approved: 526,212 for, 205,773 against, 4,853 abstain.","Auditor WithumSmith+Brown ratified: 2,193,452 for, 159,569 against, 39,556 abstain.","Adjournment proposal passed but no adjournment motion made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230612,"accession_number":"0001104659-24-071337","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"TransCode shareholders reject reverse stock split; stock plan amendment approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split (1:2 to 1:40) failed: 1,018,164 for, 1,277,915 against, 96,498 abstain.","Stock plan amendment passed: 526,212 for, 205,773 against; adds 3,000,000 shares for issuance.","All four director nominees elected (Calais, Fitzgerald, Manting, Marquet) with ~595K-597K votes for.","Auditor WithumSmith+Brown ratified: 2,193,452 for, 159,569 against, 39,556 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230611,"accession_number":"0001104659-24-069605","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"TransCode Therapeutics regains Nasdaq minimum bid price compliance; hearing cancelled","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on June 3, 2024 confirming compliance with Listing Rule 5550(a)(2).","Hearing scheduled for June 25, 2024 has been cancelled.","Remains under mandatory panel monitor through January 27, 2025.","Ticker RNAZ; stock continues on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230610,"accession_number":"0001104659-24-062047","cik":1829635,"company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"TransCode Therapeutics receives Nasdaq delisting notice; hearing set for June 25, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq delisting notice due to failure to maintain minimum $1.00 bid price for 30 consecutive business days.","Company not eligible for second compliance period due to failure to meet $5M stockholders' equity requirement for initial listing.","Appealed delisting on May 14, 2024; delisting stayed pending final written decision after hearing on June 25, 2024.","Stock continues to trade on Nasdaq under symbol RNAZ; no assurance appeal will be successful."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5023106.124675835,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}